Vibativ (telavancin)
- Region
- 🇪🇺 EU
- Active substance
- telavancin
- Company
- Theravance Biopharma Ireland Umited
- Status
- Withdrawn
- Therapeutic area
- Pneumonia, Bacterial; Cross Infection
- EU approval
- Fri 02 Sep 2011
- Designations
- Additional monitoring
- Application
- EMEA/H/C/001240
- ATC
- J01XA03
- Official record
- www.ema.europa.eu
Indication
Vibativ is indicated for the treatment of adults with nosocomial pneumonia including ventilator-associated pneumonia, known or suspected to be caused by methicillin-resistant Staphylococcus aureus (MRSA). Vibativ should be used only in situations where it is known or suspected that other alternatives are not suitable. Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Vibativ Application withdrawn · Astellas Pharma Europe B. V.
Follow Vibativ
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.